Pyoderma gangrenosum (PG) affects less than 400
people each year but it can be so severe in some cases it has led to
amputation. The condition is so rare it is often misdiagnosed.
The NIHR-funded STOP GAP trial – the Study of Treatments for
Pyoderma Gangrenosum Patients – was developed by Professor Kim Thomas and
Professor Hywel Williams, Co-Directors of the Centre of Evidence Based
Dermatology based at The University of Nottingham, and Anthony Ormerod,
Professor of Dermatology and John Norrie, Professor Clinical Trials and
Biostatistics at Aberdeen University. The randomised controlled trial was
managed by the Nottingham Clinical Trials Unit and sponsored by Nottingham
University Hospitals NHS Trust.